Anti-Coagulants - Lithuania

Lithuania

The Anti-Coagulants market in Lithuania is forecasted to achieve a revenue of US$11.11m in 2024.
It is expected to exhibit a compound annual growth rate (CAGR 2024-2029) of 7.66%, leading to a market volume of US$16.07m by 2029.
When compared globally, United States is projected to generate the highest revenue, amounting to US$16,740.00m in 2024.
Lithuania is experiencing an increasing demand for anti-coagulants due to a growing elderly population and rising awareness about cardiovascular diseases.

Key regions: Australia, Japan, United States, Germany, Europe

Market

Region

Region comparison

Currency

Analyst Opinion

The Anti-Coagulants market in Lithuania has been showing steady growth in recent years.

Customer preferences: Lithuanian customers have been increasingly interested in Anti-Coagulants due to rising awareness about the health benefits of these drugs. The aging population in Lithuania has also contributed to the growth of this market, as elderly people are more likely to require anti-coagulant treatment. Additionally, the increasing prevalence of cardiovascular diseases has led to a higher demand for anti-coagulant drugs.

Trends in the market: One of the major trends in the Anti-Coagulants market in Lithuania is the shift towards newer oral anticoagulants (NOACs) from traditional anticoagulants such as Warfarin. NOACs are easier to administer and have fewer side effects, making them more popular among patients. Another trend is the increasing use of anti-coagulants for the prevention of stroke in patients with atrial fibrillation.

Local special circumstances: Lithuania has a relatively small population, which means that the market for Anti-Coagulants is also relatively small. However, the market is expected to continue growing due to the increasing demand for these drugs. Additionally, the Lithuanian government has been taking steps to improve the healthcare system in the country, which is expected to further boost the market for Anti-Coagulants.

Underlying macroeconomic factors: The Lithuanian economy has been growing steadily in recent years, which has led to an increase in healthcare spending. This has also contributed to the growth of the Anti-Coagulants market in Lithuania. Additionally, the country's accession to the European Union has led to increased competition in the pharmaceutical industry, which has resulted in lower prices for drugs, including Anti-Coagulants.

Methodology

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.